Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
This study has been completed.
Sponsor:
Astex Pharmaceuticals
Information provided by:
Astex Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00113256
First received: June 6, 2005
Last updated: October 12, 2009
Last verified: October 2009
Tracking Information | |
---|---|
First Received Date ICMJE | June 6, 2005 |
Last Updated Date | October 12, 2009 |
Start Date ICMJE | February 2005 |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE |
survival |
Original Primary Outcome Measures ICMJE | Same as current |
Change History | Complete list of historical versions of study NCT00113256 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer |
Official Title ICMJE | Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy |
Brief Summary | Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and placebo) of the study. Toxicity of the drug combination will also be evaluated. |
Detailed Description | |
Study Type ICMJE | Interventional |
Study Phase | Phase 2 Phase 3 |
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE | Pancreatic Cancer |
Intervention ICMJE | Drug: Rubitecan |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Completed |
Estimated Enrollment ICMJE | 30 |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States |
Administrative Information | |
NCT Number ICMJE | NCT00113256 |
Other Study ID Numbers ICMJE | SGI-RUB-048 |
Has Data Monitoring Committee | |
Responsible Party | David S Smith, Vice President - Regulatory Affairs & Quality Assurance, SuperGen, Inc. |
Study Sponsor ICMJE | Astex Pharmaceuticals |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Astex Pharmaceuticals |
Verification Date | October 2009 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |